06:31
Some partners of HAPPY PATIENT explain their experience in this project
05:01
Healthcare professionals explain their experience in HAPPY PATIENT project
02:21
HAPPY PATIENT Explained
01:35
WHO IS WHO in HAPPY PATIENT - NORCE Norwegian Research Centre AS
01:42
WHO IS WHO in HAPPY PATIENT - University of Southern Denmark (RUPO)
01:00
WHO IS WHO in HAPPY PATIENT - University of Groningen
01:00
WHO IS WHO in HAPPY PATIENT - Mano Seimos Gydytojas
01:00
WHO IS WHO in HAPPY PATIENT? - REGION Hovedstaden
01:09
Carl Llor INTERVIEW: As a health care professional, how can I participate in the project?
01:25
Carl Llor INTERVIEW: The COVID-19 pandemic is providing us with an opportunity?
02:20
Carl Llor INTERVIEW: What is the so-called APO Methodology?
02:13
Carl Llor INTERVIEW: How can differences in prescription between countries be explained?
02:16
Carl Llor INTERVIEW: With how many levels of care are you planning to work with?
02:14
Carl Llor INTERVIEW: How are you planning to achieve HAPPY PATIENT's goals?
01:44
Carl Llor INTERVIEW: What is the HAPPY PATIENT project about?
01:35
Carl Llor INTERVIEW: Why is Antimicrobial resistance so important?
02:04
Carl Llor INTERVIEW: How are you planning to achieve HAPPY PATIENT's goals?
01:25
HAPPY PATIENT - EU Project (DANISH)
01:25
HAPPY PATIENT - EU Project (DUTCH)
01:19
HAPPY PATIENT - EU Project (SPANISH)
01:29
HAPPY PATIENT - EU Project (CATALAN)
01:23
HAPPY PATIENT - EU Project (POLISH)
01:19
HAPPY PATIENT - EU Project
X
About
The current misleading antibiotics prescription in many European countries is one of the biggest threats to western societies. Up to 25,000 people die every year in Europe as a direct consequence of the misuse of antibiotics, a figure that rises up to 30,000 in the United States (European Centre for Disease Prevention and Control).
The HAPPY PATIENT project is a 3 year Project co-funded by the 3rd Health Programme of the European Union under the Grant Agreement number: 900024. HAPPY PATIENT seeks to reduce the impact of antimicrobial resistance (AMR) by decreasing the inappropriate use of antimicrobials for the management of common community-acquired infections.
Tags